Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Psoriasis × deucravacitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

deucravacitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06281106 2025-04-02

TYPP

Centre Hospitalier Universitaire Vaudois

Phase 2/3 Terminated

Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡